Literature DB >> 11425938

Use and cost of outpatient visits of AD patients: CERAD XXII.

G Fillenbaum1, A Heyman, B L Peterson, C F Pieper, A L Weiman.   

Abstract

OBJECTIVE: To determine the probability, frequency, and cost of outpatient visits of patients with AD in the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) as a function of stage of dementia and institutional status.
METHODS: Clinical information on 388 patients with AD enrolled in CERAD who had no serious comorbidities at baseline and for whom the stage of disease and institutional status were known, were linked to Health Care Financing Administration Physician/Supplier and Outpatient Standard Analytic (institutional outpatient) files for 1991 through 1995. None was registered in a health maintenance organization. Repeated measures regression models were used to examine the relationship of stage of disease to probability, frequency, and cost of outpatient visits for institutionalized and noninstitutionalized patients, with demographic characteristics and calendar time controlled.
RESULTS: The annual proportion of patients with AD and a Medicare-reimbursed outpatient visit ranged from 81% to 95% and was not related to stage of dementia or institutional status. Among those with at least one outpatient visit, however, those living at home had fewer visits than did those in institutions, but their number of visits increased as dementia worsened. Those in institutions had a larger number of outpatient visits, but these did not vary significantly by stage of dementia. Neither location of residence nor stage affected the cost of outpatient visits.
CONCLUSION: Among those with an outpatient visit, the frequency of visits and their relationship to stage of disease depends on institutional status.

Entities:  

Mesh:

Year:  2001        PMID: 11425938     DOI: 10.1212/wnl.56.12.1706

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  3 in total

1.  Relationship between global severity of patients with Alzheimer's disease and costs of care in Spain; results from the co-dependence study in Spain.

Authors:  J Darbà; L Kaskens; L Lacey
Journal:  Eur J Health Econ       Date:  2014-10-28

2.  Cost of dementia in Medicare managed care: a systematic literature review.

Authors:  Paul Fishman; Norma B Coe; Lindsay White; Paul K Crane; Sungchul Park; Bailey Ingraham; Eric B Larson
Journal:  Am J Manag Care       Date:  2019-08-01       Impact factor: 2.229

Review 3.  Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.

Authors:  Linus Jönsson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.